or Try an Advanced Search...

    Technical Analysis for NRBO - NeuroBo Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 4.54 -6.20% -0.30
    NRBO closed down 6.2 percent on Monday, July 1, 2024, on 2.81 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical NRBO trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    180 Bullish Setup Bullish Swing Setup -6.20%
    Slingshot Bullish Bullish Swing Setup -6.20%
    Calm After Storm Range Contraction -6.20%
    Upper Bollinger Band Walk Strength -6.20%
    Wide Bands Range Expansion -6.20%
    Above Upper BB Strength -6.20%
    Older End-of-Day Signals for NRBO ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 9 hours ago
    Down 3% about 9 hours ago
    Down 2 % about 9 hours ago
    Down 1% about 9 hours ago
    60 Minute Opening Range Breakdown about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    NRBO Chart by TradingView
    Basic chart:

    Profile

    Researches and develops disease-modifying therapies for neurodegenerative diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biology Organ Systems Neuroscience Stem Cell Neurodegenerative Diseases Degenerative Disease Neurodegeneration Senescence

    Is NRBO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial
    Jun 26 NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
    Jun 25 NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Jun 24 NeuroBo Pharma prices private placement and direct offering to raise up to $70M
    Jun 24 NeuroBo Pharmaceuticals Announces Private Placement, Registered Direct Offering
    Jun 24 NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Jun 22 NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
    May 28 NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024
    May 9 NeuroBo Pharmaceuticals GAAP EPS of -$1.32
    May 9 NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
    See more NRBO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.7499
    52 Week Low 2.9
    Average Volume 64,928
    200-Day Moving Average 3.98
    50-Day Moving Average 3.96
    20-Day Moving Average 4.13
    10-Day Moving Average 4.32
    Average True Range 0.41
    RSI (14) 59.84
    ADX 15.66
    +DI 25.61
    -DI 17.92
    Chandelier Exit (Long, 3 ATRs) 4.07
    Chandelier Exit (Short, 3 ATRs) 4.55
    Upper Bollinger Bands 4.80
    Lower Bollinger Band 3.47
    Percent B (%b) 0.81
    BandWidth 32.08
    MACD Line 0.17
    MACD Signal Line 0.08
    MACD Histogram 0.0856
    Fundamentals Value
    Market Cap 22.03 Million
    Num Shares 4.85 Million
    EPS -43.82
    Price-to-Earnings (P/E) Ratio -0.10
    Price-to-Sales 0.00
    Price-to-Book 1.03
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.29
    Resistance 3 (R3) 5.37 5.20 5.17
    Resistance 2 (R2) 5.20 5.01 5.16 5.12
    Resistance 1 (R1) 4.87 4.89 4.79 4.79 5.08
    Pivot Point 4.70 4.70 4.66 4.66 4.70
    Support 1 (S1) 4.37 4.51 4.29 4.29 4.00
    Support 2 (S2) 4.20 4.39 4.16 3.96
    Support 3 (S3) 3.87 4.20 3.92
    Support 4 (S4) 3.79